Trial Search Results

A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)

The objectives of this study are to evaluate the safety and efficacy of Zimura intravitreal administration in patients with geographic atrophy secondary to age-related macular degeneration (AMD)

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

IVERIC bio, Inc.

Stanford Investigator(s):


  • Drug: Zimura
  • Drug: Sham


Phase 3


Inclusion Criteria:

   - Subjects of either gender aged ≥ 50 years

   - Diagnosis of Non-foveal GA secondary to dry AMD

Exclusion Criteria:

   - Any prior treatment for AMD (dry or wet) or any prior intravitreal treatment for any
   indication in either eye, except oral supplements of vitamins and minerals

   - Any intraocular surgery or thermal laser within 3 months of trial entry.

   - Any prior thermal laser in the macular region, regardless of indication

   - Any ocular or periocular infection (including blepharitis), or ocular surface
   inflammation in the past 12 weeks.

   - Previous therapeutic radiation in the region of the study eye

   - Any sign of diabetic retinopathy in either eye

Ages Eligible for Study

50 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting